In this episode, we explore CellBxHealth PLC's strategy in the liquid biopsy market, focusing on their shift from circulating tumour DNA (ctDNA) to circulating tumour cells (CTCs) with the Parsortix platform. The company has announced a significant corporate reset, including a 60% workforce reduction, while aiming for profitability by late 2028. Their focus is on addressing the limitations of traditional tissue biopsies and ctDNA tests, enhancing patient outcomes through live cell technology. Key partnerships with firms like Myriad Genetics and Roche are central to their strategy, targeting high-volume customers and refining diagnostic processes. The success of this pivot rests on proving clinical utility and transforming diagnostic failures into actionable insights for cancer treatment.